Hair Thinning: Labs, Diagnosis, and Next Steps

Why Hair Thins: The Biology Behind the Shed

Hair thinning results from disruption of the hair growth cycle, which moves through anagen (growth), catagen (regression), and telogen (rest) phases. Anything that shortens anagen or pushes follicles prematurely into telogen produces visible thinning. The trigger might be hormonal, nutritional, autoimmune, or genetic.

Each follicle operates on its own clock. A single insult, like a thyroid crash or acute iron loss, can synchronize hundreds of follicles into telogen simultaneously. That synchronization is why patients often notice a sudden increase in shedding 2 to 4 months after a triggering event. The medical term for this pattern is telogen effluvium, and it accounts for a large share of acute, diffuse hair loss in both sexes [1].

Androgenetic alopecia follows a different mechanism. Dihydrotestosterone (DHT) binds androgen receptors on genetically susceptible follicles, progressively miniaturizing them over years. In men, this produces the familiar frontal and vertex recession. In women, the pattern is typically diffuse thinning along the central part, classified using the Ludwig scale [2]. A 2019 review in the Journal of the American Academy of Dermatology estimated that androgenetic alopecia affects approximately 80% of Caucasian men and 40% of women over a lifetime [3].

Less common but clinically important causes include alopecia areata (autoimmune, patchy), frontal fibrosing alopecia (scarring), and traction alopecia from chronic tension on hair shafts. Recognizing which category applies determines the entire downstream plan.

The Lab Panel Your Clinician Should Order

A focused blood draw can rule in or rule out the most common systemic drivers of hair thinning. The goal is not to run every test available. It is to match the clinical picture to the right targets.

Iron studies (ferritin, serum iron, TIBC). Ferritin is the single most useful nutritional marker in hair loss workups. A 2022 meta-analysis in Dermatology and Therapy found that patients with telogen effluvium had significantly lower ferritin levels than controls, with a pooled mean difference of 20.18 ng/mL [4]. Many dermatologists target a ferritin level above 40 ng/mL for hair regrowth, though no universal cutoff exists. Dr. Wilma Bergfeld, a dermatologist at Cleveland Clinic, has stated: "A ferritin level of 70 ng/mL or above is what I aim for in my hair loss patients, because follicle cells divide rapidly and need iron" [5].

Thyroid panel (TSH, free T4, free T3). Both hypothyroidism and hyperthyroidism cause diffuse, non-scarring alopecia. The American Thyroid Association recommends TSH as the primary screening test [6]. When TSH falls outside the 0.4 to 4.0 mIU/L range, free T4 and free T3 help clarify whether the dysfunction is clinical or subclinical.

Androgens (total testosterone, free testosterone, DHEA-S). In women with pattern thinning, mildly elevated androgens may point toward polycystic ovary syndrome (PCOS) or adrenal hyperplasia. The Endocrine Society's 2018 guideline recommends measuring total testosterone in women when clinical hyperandrogenism is suspected [7].

CBC. A complete blood count screens for anemia, which can compound the effects of low ferritin on hair follicle metabolism.

25-hydroxyvitamin D. Vitamin D receptors are expressed in hair follicle keratinocytes. A 2019 systematic review in Dermatology Online Journal reported that patients with alopecia areata had significantly lower serum vitamin D levels compared to healthy controls [8]. Levels below 30 ng/mL warrant supplementation.

Zinc. Less commonly ordered but relevant when dietary intake is restricted or when malabsorption is suspected. A 2013 study in Annals of Dermatology found lower zinc levels in patients with all types of hair loss compared to controls [9].

Reading Your Results: What the Numbers Mean

Lab values without context are just numbers. The pattern of abnormalities matters more than any single result.

A low ferritin with normal hemoglobin suggests early iron depletion before frank anemia develops. This is common in menstruating women and frequent blood donors. Replacing iron stores with oral ferrous sulfate 325 mg daily (taken with vitamin C for absorption) often slows shedding within 3 to 4 months [4].

An elevated TSH above 4.0 mIU/L with low free T4 confirms primary hypothyroidism. Levothyroxine replacement at a starting dose of 1.6 mcg/kg/day typically normalizes thyroid function within 6 to 8 weeks, with hair regrowth following over the next several months [6]. A mildly elevated TSH (4.0 to 10.0 mIU/L) with normal free T4 is subclinical hypothyroidism. Treatment decisions here depend on symptoms, antibody status, and patient preference.

Elevated DHEA-S with normal testosterone suggests an adrenal source of excess androgens. Elevated total testosterone with a low sex hormone-binding globulin (SHBG) increases bioavailable androgens, which can accelerate miniaturization even when total testosterone appears within the reference range. In women, the Endocrine Society notes that a total testosterone above 150 ng/dL warrants investigation for an androgen-secreting tumor [7].

Normal labs with a clear pattern of bitemporal recession or vertex thinning in a man strongly suggests androgenetic alopecia, which is primarily a clinical diagnosis. No lab test confirms it. The diagnosis rests on pattern, family history, and sometimes dermoscopy showing follicular miniaturization.

The Clinical Exam: What Your Doctor Looks For

Labs are half the picture. The physical examination supplies the other half, and for many types of hair thinning, it is the more informative half.

Pull test. The clinician grasps about 60 hairs between thumb and forefinger and tugs gently. Extracting more than 6 hairs (about 10%) suggests active shedding consistent with telogen effluvium or anagen effluvium [1]. This is a simple, no-cost test performed in the office.

Dermoscopy (trichoscopy). A handheld dermatoscope magnifies the scalp 10 to 70 times. In androgenetic alopecia, the hallmark finding is hair diameter variability greater than 20%, meaning thick terminal hairs intermixed with thin vellus-like hairs [10]. In alopecia areata, the clinician may see exclamation-point hairs (short, broken shafts that taper proximally) and yellow dots (keratotic plugs in empty follicles).

Part width assessment. Widening of the central part compared to the occipital part is a reliable visual indicator of female pattern hair loss. The Sinclair scale grades this from 1 (normal) to 5 (severe midline widening with visible scalp) [10].

Scalp biopsy. Reserved for cases where the diagnosis remains unclear after labs and clinical exam. A 4 mm punch biopsy sent for both horizontal and vertical sectioning can distinguish between non-scarring alopecias (telogen effluvium, androgenetic alopecia) and scarring alopecias (lichen planopilaris, frontal fibrosing alopecia) by assessing the terminal-to-vellus hair ratio and looking for perifollicular fibrosis or inflammation [2].

Telogen Effluvium: The Most Common Acute Cause

Telogen effluvium (TE) is the most frequent reason for an acute increase in hair shedding. It results from a systemic stressor that shifts a large percentage of follicles from anagen into telogen simultaneously.

Common triggers include major surgery, high fever (including COVID-19), rapid weight loss exceeding 20 pounds, childbirth, discontinuation of oral contraceptives, severe emotional stress, and nutritional deficiencies [1]. The shedding typically begins 2 to 4 months after the insult and resolves spontaneously within 6 to 9 months once the trigger is removed.

A 2021 study in the Journal of the American Academy of Dermatology documented that 22% of hospitalized COVID-19 patients developed telogen effluvium, with a median onset of 58 days after symptom onset [11]. This established COVID-19 as one of the most common single triggers of TE in recent years.

Treatment is cause-directed. Correct the iron deficiency. Treat the thyroid disorder. Optimize protein intake. Time alone resolves most cases. Minoxidil may accelerate recovery, though the evidence for its use specifically in TE is limited to small studies.

Chronic TE, defined as shedding persisting beyond 6 months without an identifiable ongoing trigger, is a distinct entity that can be frustrating for patients and clinicians alike. The British Association of Dermatologists' 2023 guideline on hair loss management notes: "Chronic telogen effluvium is a diagnosis of exclusion requiring repeat investigation to rule out evolving androgenetic alopecia or occult systemic disease" [12].

Androgenetic Alopecia: Treatments That Work

Androgenetic alopecia (AGA) is progressive. Without intervention, miniaturization continues. The evidence base for treatment is stronger here than for any other form of hair thinning.

Finasteride (men). A type II 5-alpha reductase inhibitor that reduces serum DHT by approximately 70%. The key Kaufman trial (N=1,553) demonstrated that finasteride 1 mg daily increased hair count by a mean of 107 hairs per 1-inch circle at 2 years, while placebo-treated men lost 75 hairs in the same area [13]. Sexual side effects (decreased libido, erectile dysfunction) occurred in 1.4% to 1.8% of treated men vs. 0.9% to 1.3% on placebo. The FDA approved finasteride 1 mg for male AGA in 1997.

Minoxidil (men and women). A potassium channel opener that prolongs anagen. Topical minoxidil 5% applied twice daily is FDA-approved for both sexes. A 48-week randomized trial (N=381) showed that 5% minoxidil produced a mean increase of 18.6 hairs per cm² vs. 12.7 for 2% minoxidil in men [14]. Oral minoxidil at low doses (0.25 to 5 mg daily) has gained traction as an off-label alternative, particularly in women who find topical application impractical. A 2022 systematic review in the Journal of the American Academy of Dermatology analyzed 17 studies and found oral minoxidil effective at doses as low as 0.25 mg daily in female AGA, with hypertrichosis as the most common side effect [15].

Spironolactone (women). An androgen receptor antagonist used off-label for female AGA at doses of 100 to 200 mg daily. A 2020 retrospective study of 174 women treated with spironolactone found that 74% showed clinical improvement over a median follow-up of 11.5 months [16]. Contraindicated in pregnancy due to anti-androgenic effects on a male fetus. Potassium monitoring is required.

Dutasteride (men, off-label). Inhibits both type I and type II 5-alpha reductase, reducing DHT by over 90%. A phase III Korean trial (N=917) found dutasteride 0.5 mg superior to finasteride 1 mg in hair count improvement at 24 weeks, with a mean increase of 12.2 hairs/cm² vs. 8.3 for finasteride [17]. Not FDA-approved for AGA but prescribed off-label in many countries.

Procedures. Platelet-rich plasma (PRP) injections have moderate evidence supporting their use as adjunctive therapy. A 2019 meta-analysis in Dermatologic Surgery pooled 8 RCTs and found PRP significantly increased hair density compared to placebo, though protocols varied widely [18]. Low-level laser therapy (LLLT) devices are FDA-cleared, with modest efficacy data.

When to Worry: Red Flags That Need Urgent Workup

Most hair thinning is benign and treatable. But certain patterns signal conditions that require prompt evaluation.

Rapid onset of patchy, smooth bald spots suggests alopecia areata. While alopecia areata itself is not dangerous, it can be associated with thyroid autoimmunity (present in 8% to 28% of patients, depending on the study) and other autoimmune conditions [19]. Screening with TSH and thyroid peroxidase (TPO) antibodies is standard.

Scarring at the hairline, particularly in postmenopausal women, raises concern for frontal fibrosing alopecia (FFA). Progression of FFA can be permanent. Early treatment with hydroxychloroquine or a 5-alpha reductase inhibitor may slow advancement, but a dermatology referral is time-sensitive [2].

Sudden, diffuse hair loss in a child or adolescent should prompt evaluation for tinea capitis (fungal infection), trichotillomania (hair-pulling disorder), or nutritional deficiency. A KOH preparation and fungal culture can rule out tinea.

Hair thinning accompanied by virilization in a woman (deepening voice, acne, clitoromegaly, rapid-onset hirsutism) warrants urgent measurement of total testosterone and DHEA-S. A total testosterone level above 200 ng/dL in a woman raises suspicion for an androgen-secreting ovarian or adrenal tumor and requires imaging [7].

Building Your Treatment Timeline

Recovery from hair thinning is not fast. Setting realistic expectations matters because premature discontinuation of effective therapy is one of the most common reasons for treatment failure.

Month 1 to 2. Labs drawn and reviewed. Nutritional deficiencies corrected. Thyroid medication initiated if needed. Topical or oral minoxidil started. Possible initial increase in shedding (minoxidil-induced telogen release) that typically resolves by week 8.

Month 3 to 4. Finasteride or spironolactone effects begin. New anagen hairs are growing but may not yet be visible. Iron and vitamin D levels rechecked at the 3-month mark.

Month 6. First meaningful assessment point. Hair counts or standardized photography compared to baseline. The Kaufman finasteride trial showed statistically significant improvement at 6 months, with continued gains through 24 months [13].

Month 12 and beyond. Full treatment effect for most pharmacologic agents. Maintenance therapy is typically indefinite for AGA, since discontinuation leads to resumption of miniaturization within 6 to 12 months. TE patients with resolved triggers can generally stop treatment once regrowth stabilizes.

TSH should be rechecked every 6 to 12 months in patients on levothyroxine. Ferritin should be monitored annually in patients with a history of iron deficiency. Potassium should be checked within the first month and then every 6 months for patients on spironolactone.